Hepatitis A and B vaccine
Twinrix is a vaccine against hepatitis A and hepatitis B, manufactured by GlaxoSmithKline. Twinrix is administered over three doses.
The name was created because it is a mixture of two earlier vaccines — Havrix, an inactivated-virus Hepatitis A vaccine, and Engerix-B, a recombinant Hepatitis B vaccine. Twinrix, Havrix and Engerix-B are registered trademarks of GlaxoSmithKline; if the same vaccine is available from others, it will have another name. Twinrix first entered the market in early 1997.[citation needed]
Administration schedule
Twinrix can be administered on the same schedule as monovalent Hepatitis B vaccine: at 0- 1- and 6- months. In some circumstances, an accelerated dosing schedule of 0- 7- and 21-to 30- days followed by a booster at 12 months can be used and is believed to have similar efficacy as the traditional schedule.[1]
Efficacy
The CDC reports that clinical trials found the following levels of protection against Hep A and Hep B one month after each dose:[2]
- A: 93.8%, 98.8%, 99.9%
- B: 30.8%, 78.2%, 98.5%
GlaxoSmithKline claims that its studies found 70% of subjects had antibodies against hepatitis B a month after just the first dose, however.[3]
See also
References
- ^ http://us.gsk.com/products/assets/us_twinrix.pdf
- ^ "FDA approval for a combined hepatitis A and B vaccine". MMWR Morb. Mortal. Wkly. Rep. 50 (37): 806–7. September 2001. PMID 11785573.
- ^ Twinrix Adult Vaccine, SPC from the eMC
External links
| Subsidiaries |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Predecessors, acquisitions | |||||||||
| Products |
| ||||||||
| People |
| ||||||||
| Litigation | |||||||||
| Other | |||||||||
